DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)

Key facts

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Principal Investigator

Marina Baretti, MD

SKCCC • Johns Hopkins Medical Institution

Intervention

Durvalumab(drug)

Enrollment

27 enrolled

Eligibility

12 years · All sexes

Timeline

2024 – 2033

Study locations (1)

• Johns Hopkins SKCCC, Baltimore, Maryland, United States

Collaborators

Dracen Pharmaceuticals, Inc. · Fibrolamellar Cancer Foundation

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Fibrolamellar hepatocellular carcinoma

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1NCT06789198
  Peptide Vaccine for Fibrolamellar Hepatocellular Carcinoma Patients and Other Tumor Entities Carrying the Driver Fusion DNAJB1-PRKACA
  University Hospital Tuebingen
• RECRUITINGPHASE1, PHASE2NCT06620302
  Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma
  Children's Oncology Group
• RECRUITINGPHASE1NCT05937295
  FusionVAC22_01: Fusion Transcript-based Peptide Vaccine Combined with Immune Checkpoint Inhibition
  University Hospital Tuebingen
• RECRUITINGPHASE1, PHASE2NCT05468359
  Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
  St. Jude Children's Research Hospital
• RECRUITINGPHASE1, PHASE2NCT04380545
  Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer
  M.D. Anderson Cancer Center
• RECRUITINGPHASE2NCT04134559
  Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma
  Allison O'Neill, MD

See all trials for Fibrolamellar hepatocellular carcinoma →